Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer

机译：雷莫昔单抗联合紫杉醇治疗不可切除和复发性胃癌的临床价值

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionRecently in Japan, Ramucirumab (RAM) became the first anti-angiogenic agent to be approved for second-line treatment of gastric cancer. In the present study, we aimed to evaluate the efficacy and safety of RAM plus paclitaxel (PTX) in patients with unresectable and recurrent gastric cancer in our institution.

机译：前言在日本，雷米库单抗（RAM）成为第一种被批准用于胃癌二线治疗的抗血管生成剂。在本研究中，我们旨在评估RAM加紫杉醇（PTX）在我们机构中不可切除和复发性胃癌患者中的疗效和安全性。

著录项

期刊名称 Fukushima Journal of Medical Science
作者
Suguru Hayase; Leo Yamada; Daisuke Ujiie; Azuma Nirei; Takeshi Tada; Hiroyuki Hanayama; Tomoyuki Monma; Zenichiro Saze; Shinji Ohki; Koji Kono;
展开▼
作者单位

展开▼
年(卷),期 2019(65),1
年度 2019
页码 6–12
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
ramucirumab paclitaxel elderly chemotherapy advanced gastric cancer;

机译：雷莫昔单抗;紫杉醇;老年人;化疗;晚期胃癌;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer [J] . Kimura Michio, Usami Eiseki, Teramachi Hitomi, Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2018,第6期

机译：Ramucirumab加上紫杉醇化疗治疗先进和复发性胃癌的成本效益和安全性
2. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites [J] . Hiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, BMC Cancer . 2018,第1期

机译：回顾性研究紫杉醇加紫苏尿液与腹水先进或复发胃癌患者的安全性和疗效研究
3. Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel [J] . Hyung-Don Kim, Min-Hee Ryu, Sangsoon Yoon, 中国癌症研究（英文版） . 2020,第005期

机译：雷莫昔单抗联合紫杉醇治疗胃癌患者中性粒细胞与淋巴细胞比例和MDSC动力学的临床意义
4. pilot Study of a Combination Immunochemotherapy with TS-1 and Lentinan in Unresectable and Recurrent Gastric Cancer [C] . S. Iijima, Y. Kimura, E. Kurokawa, International Gastric Cancer Congress . 2005

机译：TS-1和Lentinan在不可切除和复发性胃癌中的组合免疫化学治疗的试验研究
5. Clinical and Economic Outcomes for Gastric Cancer Patients Treated with Gastrectomy at Centres with and without Cancer Surgery Designation in Ontario [D] . Jeong, Yunni . 2019

机译：安大略省患有癌症手术指定胃癌治疗胃癌患者的胃癌患者的临床和经济结果
6. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group [O] . Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, 2020

机译：每周紫杉醇联合雷莫昔单抗与每周纳布紫杉醇联合雷莫西单抗治疗无法切除的晚期或复发性胃癌但一线治疗难治性腹膜扩散-P-SELECT试验（WJOG10617G）-西日本肿瘤学小组的一项随机II期试验
7. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group [O] . Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, 2020

机译：每周Paclitaxel Plus Ramucirumab与每周Nab-Paclitaxel加上Ramucirumab与腹膜传播难以进行一线治疗 - P-SELECT试验（WJOG10617G）-A由西日本肿瘤学组进行随机化第二次审判

Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer

摘要

著录项

相似文献

相关主题

期刊订阅